As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, ...

Medicare is expanding its drug price negotiation program to include 15 more medications, including popular drugs like Ozempic ...

The Centers for Medicare & Medicaid Services (CMS) is developing a pilot program that could change the landscape of obesity ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

If the plan pans out, it would be an enormous boon to Eli Lilly and Novo Nordisk. Currently, many health insurance plans, as ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

A groundbreaking initiative from the Trump administration could revolutionize access to costly weight-loss drugs under Medicare and Medicaid. This plan aims to provide millions of Americans suffering ...

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...